Program
Posters will be available for on-demand viewing starting at 9:30 am U.S. ET on Wednesday, February 3.
Wednesday, february 3, 2021
Welcome and Opening Keynote Address
10-10:30 A.m.
Welcome and Introduction of Keynote Speaker
E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania
Messenger RNA vaccines
Ugur Sahin, BioNTech SE, Mainz, Germany
Break
10:30-10:45 A.M.
Symposium 1: Intersection of the Biology of COVID-19 and Cancer
10:45 A.M.-12:35 p.m.
Introduction
Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York
Nihal Altan-Bonnet, National Heart, Lung, and Blood Institute, Bethesda, Maryland
The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score*
Gino Dettorre, Imperial College London, London, England
Nevile Sanjana, New York University Langone Medical Center, New York, New York
Closing Remarks / Discussion
Symposium 2: Cancer Prevention and Early Detection during the COVID-19 Pandemic
10:45 A.M.-12:35 P.M.
Introduction
Ana Maria Lopez, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania
Mary E. Reid, Roswell Park Comprehensive Cancer Center, Buffalo, New York
Katherine D. Crew, Columbia University, New York, New York
Closing Remarks / Discussion
Break
12:35-12:50 p.m.
Forum 1: Cancer Trial Design/Experience During COVID-19
Moderator: Robert L. Ferris, University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania
1-2 P.M.
Panelists:
Michael Kurllia, National Center for Advancing Translational Sciences, Bethesda, Maryland
Jason J. Luke, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Worta McCaskill-Stevens, National Cancer Institute, Rockville, Maryland
Forum 2: When Should Patients With Cancer Be Vaccinated?
Moderator: Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, California
1-2 P.M.
Panelists:
Marina C. Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Jia Luo, Memorial Sloan Kettering Cancer Center, New York, New York
E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania
Additional panelist to be announced
Break
2-2:15 p.m.
Symposium 3: COVID-19 Immunology and Pathogenesis
2:15-4:05 P.M.
Introduction
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York
James R. Heath, Institute for Systems Biology, Seattle, Washington
Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study*
Lewis Au, The Francis Crick Institute, London, England
Spatial profiling of lung SARS-CoV-2 and influenza virus infection identifies virus specific host responses and gene signatures*
Arutha Kulasinghe, Queensland University of Technology, Brisbane, Australia
Stanley Pearlman, University of Iowa, Iowa City, Iowa
Closing Remarks / Discussion
Symposium 4: COVID-19 Long-term Effects and Impact on Cancer Survivorship
2:15-4:05 P.M.
Introduction
Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, California
Larissa Nekhlyudov, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts
Effects of demographic and behavioral factors on social isolation in a cancer center population during COVID-19 pandemic*
Shelley Tworoger, Moffitt Cancer Center, Tampa, Florida
Closing Remarks / Discussion
Thursday, February 4, 2021
Keynote Address
10-10:25 a.m.
Introduction of Keynote Speaker
Jeffrey S. Morris, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Keynote Address
Peter Marks, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
Break
10:25-10:45 a.m.
Symposium 5: Cancer Drug Repurposing to Treat COVID-19
10:45 A.M.-12:35 P.M.
Introduction
Fabrice Barlesi, INSERM U1030 – Gustave Roussy Institute, Villejuif, France
Nevan J. Krogan, UCSF School of Medicine, San Francisco, California
David Fajgenbaum, University of Pennsylvania, Philadelphia, Pennsylvania
Closing Remarks / Discussion
Symposium 6: Continuity of Cancer Care
10:45 A.M.-12:35 P.M.
Introduction
Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Trisha Wise-Draper, University of Cincinnati, Cincinnati, Ohio
Telehealth experiences of adolescent and young adult cancer patients and survivors during the COVID-19 pandemic*
Karely Mann, Huntsman Cancer Institute, Salt Lake City, Utah
Giuseppe Curigliano, University of Milan, Milan, Italy
Closing Remarks / Discussion
Break
12:35-12:50 p.m.
Forum 3: Adaptive Trial Design / ICU
1-2 p.m.
Panelists to be announced
Forum 4: Telehealth
Moderator: Ana Maria Lopez, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania
1-2 P.M.
Panelists:
Elizabeth A. Krupinski, Emory University, Atlanta, Georgia
Hanna K. Sanoff, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Ronald S. Weinstein, University of Arizona, Tucson, Arizona
Break
2-2:15 p.m.
Symposium 7: COVID-19 Vaccines
2:15-4:05 P.M.
Introduction
Deepta Bhattacharya, University of Arizona Cancer Center, Tucson, Arizona
Randall N. Hyer, Moderna, Cambridge, Massachusetts
Katie Ewer, University of Oxford, Oxford, England
Michela Locci, University of Pennsylvania, Philadelphia, Pennsylvania
Closing Remarks / Discussion
Symposium 8: Critical Care and Outpatient Management of COVID-19 and Cancer Patients
2:15-4:05 P.M.
Introduction
Louis P. Voigt, Memorial Sloan Kettering Cancer Center, New York, New York
Cristina Gutierrez, The University of Texas MD Anderson Cancer Center, Houston, Texas
Sanjay Chawla, Memorial Sloan Kettering Cancer Center, New York, New York
Elie Azoulay, Hôpital St Louis, Paris, France
Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, New York
Closing Remarks / Discussion
Friday, FEBRUARY 5, 2021
Keynote Address
10-10:25 a.m.
Introduction of Keynote Speaker
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
Prolonged virus shedding and virus-induced lymphopenia are detrimental in cancer patients
Laurence Zitvogel, Gustave Roussy, Villejuif, France
Break
10:25-10:45 a.m.
Symposium 9: Effects of Cancer Treatments on COVID-19
10:45 A.M. -12:35 P.M.
Introduction
Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Santosha A. Vardhana, Memorial Sloan Kettering Cancer Center, New York, New York
Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, Massachusetts
Closing Remarks / Discussion
Symposium 10: Health Inequities and Disparities in the COVID-19 Pandemic
10:45 A.M. -12:35 P.M.
Introduction
John M. Carethers, University of Michigan, Ann Arbor, Michigan
Karen M. Winkfield, Meharry-Vanderbilt Alliance, Nashville, Tennessee
Financial hardship and mental health among cancer survivors during the COVID-19 pandemic: An analysis of the US COVID Impact Survey*
Jessica Islam, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Disparities in food insecurity among cancer survivors during the U.S. COVID-19 pandemic*
Marlene Camacho-Rivera, SUNY Downstate Health Sciences University, Brooklyn, New York
Michael T. Halpern, National Cancer Institute, Bethesda, Maryland
Closing Remarks / Discussion
Break
12:35-12:50 P.M.
Forum 5: Workforce Issues
Moderator: Elizabeth M. Jaffee, Johns Hopkins University, Baltimore, Maryland
1-2 p.m.
Panelists:
Dinah S. Singer, National Cancer Institute, Bethesda, Maryland
Cheryl L. Willman, University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico
Robert A. Winn, VCU Massey Cancer Center, Richmond, Virginia
Break
2-2:15 p.m.
Symposium 11: Risk Factors and Comorbidities Resulting in Adverse Outcomes FOR CANCER PATIENTS WITH COVID-19
2:15-4:05 P.M.
Introduction
Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, New York
Miguel-Angel Perales, Memorial Sloan Kettering Cancer Center, New York, New York
Using CXR-Net to detect COVID-19 and non-COVID-19 patients*
Abdulah Haikal, Wayne State University School of Medicine, Detroit, Michigan
Tian Zhang, Duke University School of Medicine, Durham, North Carolina
Closing Remarks / Discussion
Symposium 12: Epidemiology and Registries of COVID-19 and Cancer
2:15-4:05 P.M.
Introduction
Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, California
Quantifying the impact of COVID-19 on cancer care: Pathology volume change in SEER cancer registries*
Todd Golden, National Cancer Institute, Bethesda, Maryland
Comprehensive meta-analysis of COVID-19 mortality rates for 22 cancer subtypes from the Reboot: COVID-Cancer Project, an interactive resource with aggregated data from 21,839 cancer patients*
Catherine Del Vecchio Fitz, Reboot Rx, Boston, Massachusetts
Clinical and demographic characteristics associated with shorter time to COVID-19 death*
Maria J. Monroy-Iglesias, King’s College London, London, England
Covid-19 disease in patients with lung cancer in Spain: GRAVID Lung Cancer Patients Disease (GRAVID study)*
Jose Maria Mazarico Gallego, Hospital Universitario 12 de Octubre, Madrid, Spain
Social Determinants of Health (SDOH) barriers as predictors of intent to vaccinate for COVID-19 in a vulnerable population*
Beth A. Jones, Yale University School of Public Health, New Haven, Connecticut
Closing Remarks / Discussion
Break
4:05-4:20 P.M.
Closing Session: Emerging Topics
Moderator: Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, California
4:20-5:30 p.m.
Panelists:
Jeffrey S. Morris, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania
*Short talk from proffered papers